Board of Advisors – Ruth Wexler× Ruth Wexler Scientific and Drug Discovery Advisory Board member, Former Scientific VP, Small Molecule Drug Discovery at Bristol Myers Squibb Accomplished pharmaceutical R&D executive with a passion for discovering transformational small molecule therapeutics to help patients address unmet medical need. Currently serving as a R&D executive scientific advisor/drug discovery consultant. Significant experience leading medicinal chemistry teams and setting research strategies across a broad range of therapeutic areas, and target classes spanning, cardiovascular, neuroscience, fibrosis, metabolic and immunology drug discovery. Track record of successfully building and leading high achieving discovery teams that advanced 38 clinical candidates, including two marketed drugs for the treatment of cardiovascular disease; losartan, to treat hypertension, and Eliquis® (apixaban), a novel oral anticoagulant. Recognized as a highly collaborative scientific leader, passionate about mentoring, and developing next generation leaders and scientists with a strong commitment to diversity and inclusion. Broad experience in leading multifunctional diverse and global teams both internally, and externally with academic and biotech partners. Innovation and productivity documented by numerous awards, invited lectureships, and >250 manuscripts and patents.Specialties: Cardiovascular Drug Discovery | Leadership and Mentoring | Medicinal Chemistry | Additional leadership experience in Metabolic Diseases, Neuroscience, Fibrosis, and Immunology | In-licensing and Alliance Partnerships.